CRISPR Therapeutics CFO receives 18,000 options

The option award has an expiration date of October 26, 2036.

Rhea-AI Filing Summary

CRISPR Therapeutics AG Chief Financial Officer Andrew Jacob Silver was granted an option covering 18,000 Common Shares on October 26, 2026, with a $49.01 per-share exercise price. The option vests in 48 equal monthly installments beginning November 26, 2026. Silver also received 9,000 restricted stock units on October 26, 2026; each represents a contingent right to receive one Common Share, with one quarter vesting on each October 26 from 2027 through 2030.

Insider Trade Summary

Grant/Award: 27,000 shares

Grant/Award 2 txns

Insider Silver Andrew Jacob

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	18,000	$0.00	$0.00
Grant/Award	Restricted Stock Units F2, F3	9,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 18,000 contracts (Direct); Restricted Stock Units — 9,000 contracts (Direct)

Footnotes (3)

1. F1. This option was granted on October 26, 2026 with respect to 18,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 26, 2026.
2. F2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
3. F3. This restricted stock unit award was granted on October 26, 2026 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on October 26, 2027, (ii) one quarter of the shares vesting on October 26, 2028, (iii) one quarter of the shares vesting on October 26, 2029, and (iv) one quarter of the shares vesting on October 26, 2030.

Key Figures

Option award: 18,000 Common Shares Exercise price: $49.01 per share Option vesting: 48 equal monthly installments +3 more

6 metrics

Option award 18,000 Common Shares Granted October 26, 2026

Exercise price $49.01 per share Option granted October 26, 2026

Option vesting 48 equal monthly installments Beginning November 26, 2026

Option expiration October 26, 2036 Option granted October 26, 2026

Restricted stock unit award 9,000 restricted stock units Granted October 26, 2026

Restricted stock unit vesting One quarter at each of four annual vesting dates October 26, 2027; October 26, 2028; October 26, 2029; and October 26, 2030

Key Terms

Stock Option (Right to Buy), Restricted Stock Units, vesting

3 terms

Stock Option (Right to Buy) financial

"option was granted ... with respect to 18,000 Common Shares"

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"100% of the shares will vest in 48 equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did CRSP CFO Andrew Jacob Silver receive?

Andrew Jacob Silver received an option covering 18,000 Common Shares and 9,000 restricted stock units on October 26, 2026. The option has a $49.01 per-share exercise price.

When do Andrew Jacob Silver's CRSP equity awards vest?

The option vests in 48 equal monthly installments, beginning November 26, 2026. One quarter of the restricted stock units vests on each of October 26, 2027, October 26, 2028, October 26, 2029, and October 26, 2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/28/2026 - 05:41 PM EDT Accepted by SEC EDGAR 10/28/2026 - 05:41 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silver Andrew Jacob

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$49.01	10/26/2026		A		18,000		(1)	10/26/2036	Common Shares	18,000	$0	18,000	D
Restricted Stock Units	(2)	10/26/2026		A		9,000		(3)	(3)	Common Shares	9,000	$0	9,000	D

Explanation of Responses:

1. This option was granted on October 26, 2026 with respect to 18,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 26, 2026.

2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

3. This restricted stock unit award was granted on October 26, 2026 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on October 26, 2027, (ii) one quarter of the shares vesting on October 26, 2028, (iii) one quarter of the shares vesting on October 26, 2029, and (iv) one quarter of the shares vesting on October 26, 2030.

	Elizabeth Ryland Waldinger, attorney-in-fact	10/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)